@article{cedd127d1f3849f0a2028bcb49474c08,
title = "NCCN Guidelines{\textregistered}: Insights malignant pleural mesothelioma, version 3.2016",
abstract = "These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.",
author = "Ettinger, {David S.} and Wood, {Douglas E.} and Wallace Akerley and Bazhenova, {Lyudmila A.} and Hossein Borghaei and Camidge, {David Ross} and Cheney, {Richard T.} and Chirieac, {Lucian R.} and D'amico, {Thomas A.} and Thomas Dilling and Michael Dobelbower and Ramaswamy Govindan and Mark Hennon and Leora Horn and Jahan, {Thierry M.} and Ritsuko Komaki and Lackner, {Rudy P.} and Michael Lanuti and Rogerio Lilenbaum and Jules Lin and Loo, {Billy W.} and Renato Martins and Otterson, {Gregory A.} and Patel, {Jyoti D.} and Pisters, {Katherine M.} and Karen Reckamp and Riely, {Gregory J.} and Schild, {Steven E.} and Shapiro, {Theresa A.} and Neelesh Sharma and Swanson, {Scott J.} and James Stevenson and Kurt Tauer and Yang, {Stephen C.} and Kristina Gregory and Miranda Hughes",
note = "Funding Information: This activity is supported by educational grants from AstraZeneca, Bayer Healthcare Pharmaceuticals Inc., Bristol-Myers Squibb, Clovis Oncology, Foundation Medicine, Genentech, Novartis Oncology, Otsuka America Pharmaceutical, Inc., Seattle Genetics, Inc., and Takeda Oncology; support provided by Actelion Pharmaceuticals US, Inc.; and by an independent educational grant from Astellas and Medivation, Inc. Publisher Copyright: {\textcopyright} JNCCN - Journal of the National Comprehensive Cancer Network.",
year = "2016",
month = jul,
day = "1",
doi = "10.6004/jnccn.2016.0087",
language = "English (US)",
volume = "14",
pages = "825--836",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "7",
}